Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.

[1]  J. Uhm.  Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma , 2011 .

[2]  Alessia Pica,et al.  Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Elizabeth Eisenhauer,et al.  Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.

[4]  G. Reifenberger,et al.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Pierre-Marie Martin,et al.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[7]  C. Sommer,et al.  Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Wong.  Is protracted low-dose temozolomide feasible in glioma patients? , 2006, Neurology.

[9]  R. Mirimanoff,et al.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[11]  J. Menten,et al.  A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo)astrocytoma: An interim analysis of toxicity , 2005 .

[12]  J. Debus,et al.  Temozolomide Combined with Irradiation as Postoperative Treatment of Primary Glioblastoma Multiforme , 2005, Strahlentherapie und Onkologie.

[13]  D. Misailidou,et al.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[15]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[16]  Shiladitya Sengupta,et al.  Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. , 2003, Cancer research.

[17]  H. Choy,et al.  Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? , 2003, Journal of the National Cancer Institute.

[18]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[19]  N. Horikoshi,et al.  Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. , 2001, Cancer research.

[20]  T. Shono,et al.  Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. , 2001, Cancer research.

[21]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[22]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[23]  J. Gelin,et al.  Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. , 1994, Cancer research.

[24]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .